FrancophonIA/ELRC3.0 huggingface dataset:
English: You may need tests to check for tuberculosis before you are given Olumiant.
Danish: Det kan være, at du skal undersøges for tuberkulose, før du får Olumiant.
English: Lipid parameters should be assessed approximately 12 weeks following initiation of Olumiant therapy and thereafter patients should be managed according to international clinical guidelines for hyperlipidaemia.
Danish: Lipidparametre bør vurderes ca. 12 uger efter indledning af behandling med Olumiant, og herefter bør patienterne håndteres i overensstemmelse med internationale kliniske retningslinjer for hyperlipidæmi.
English: • The Package Leaflet including the Patient Alert Card
Danish: • Indlægsseddel inklusive Patientkort
English: Olumiant is not recommended for use in patients with creatinine clearance < 30 mL/min (see section 5.2).
Danish: Det anbefales ikke at anvende Olumiant til patienter med kreatininclearance < 30 ml/min (se pkt.
English: Radiographic response
Danish: Radiologisk respons
English: Reporting rates for Olumiant compared to placebo for the infection-related ADRs were: Upper respiratory tract infections (14.7 % vs. 11.7 %), urinary tract infections (3.4 % vs. 2.7 %), gastroenteritis (1.6 % vs. 0.8 %), herpes simplex (1.8 % vs. 0.7 %), and herpes zoster (1.4 % vs. 0.4 %).
Danish: Rapporteringsraterne for Olumiant sammenlignet med placebo for de infektionsrelaterede bivirkninger var: infektioner i øvre luftveje (14,7 % vs. 11,7 %), urinvejsinfektioner (3,4 % vs. 2,7 %), gastroenteritis (1,6 % vs. 0,8 %), herpes simplex (1,8 % vs. 0,7 %) og herpes zoster (1,4 % vs. 0,4 %).
English: RA-BUILD (24 weeks)
Danish: RA-BUILD (24 uger)
English: Laboratory measures and monitoring guidance
Danish: Laboratorieanalyser og monitoreringsvejledning
English: The recommended dose is 4 mg once a day.
Danish: Den anbefalede dosis er 4 mg én gang om dagen.
English: The risk of malignancies including lymphoma is increased in patients with rheumatoid arthritis.
Danish: Risikoen for maligniteter, herunder lymfom, er øget hos patienter med reumatoid artritis.
English: If a patient becomes pregnant while taking Olumiant the parents should be informed of the potential risk to the foetus.
Danish: Hvis en patient bliver gravid under behandling med Olumiant, skal kvinden og hendes partner informeres om den potentielle risiko for fosteret.
English: Olumiant is used to treat adults with moderate to severe rheumatoid arthritis, an inflammatory disease of the joints, if previous therapy did not work well enough or was not tolerated.
Danish: Olumiant anvendes til behandling af voksne med moderat til svær leddegigt, en inflammatorisk ledsygdom, hvis tidligere behandling ikke virkede godt nok eller ikke kunne tåles.
English: 12 weeks after initiation of treatment and thereafter according to international clinical guidelines for hyperlipidaemia
Danish: 12 uger efter indledning af behandling og herefter i overensstemmelse med internationale kliniske retningslinjer vedrørende hyperlipidæmi.
English: Therefore, the PRAC requests the MAH to update of section 4.4 of the SmPC to add a warning on hypersensitivity and to update of Section 4.8 to add the adverse reactions “rash” with a frequency common and “swelling of the face, urticaria” with a frequency uncommon.
Danish: PRAC anmoder derfor om, at MAH opdaterer afsnit 4.4 i SmPCet ved at tilføje en advarsel om overfølsomhed, samt at MAH opdaterer afsnit 4.8 ved at tilføje bivirkningerne ”udslæt” med hyppigheden almindelig, samt ”hævelse i ansigt, urticaria” med hyppigheden ikke almindelig.
English: Infections: Olumiant may make an existing infection worse or increase the chance of you getting a new infection or increase the chance of viral reactivation.
Danish: Infektioner Olumiant kan forværre en eksisterende infektion eller øge risikoen for, at du får en ny infektion eller øge risikoen for viral reaktivering.
English: Olumiant is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs.
Danish: Olumiant er indiceret til behandling af moderat til svær aktiv reumatoid artritis hos voksne patienter, der ikke har responderet tilstrækkeligt på eller ikke tåler et eller flere sygdomsmodificerende antireumatiske lægemidler (DMARDs).
English: If a patient develops herpes zoster, Olumiant treatment should be temporarily interrupted until the episode resolves.
Danish: Hvis en patient udvikler herpes zoster, bør Olumiant-behandlingen afbrydes midlertidigt, indtil episoden er gået over.
English: No clinical pharmacology study has been conducted with OAT3 inhibitors with less inhibition potential.
Danish: Der er ikke udført noget klinisk farmakologisk studie med OAT3-hæmmere med et mindre udtalt hæmningspotentiale.
English: The mean effects of intrinsic factors on PK parameters (AUC and Cmax) were generally within the inter-subject PK variability of baricitinib.
Danish: De gennemsnitlige påvirkninger fra disse faktorer på de farmakokinetiske parametre (AUC og Cmax) lå generelt inden for den inter-individuelle variabilitet i baricitinibs farmakokinetiske parametre.
English: Thrombocytosis >600 x 109 cells/Lc
Danish: Trombocytose > 600 x 109 celler/lc
English: Tell your doctor if you get symptoms such as fever, wounds, feeling more tired than usual or dental problems as these can be signs of infection.
Danish: Fortæl lægen, hvis du får symptomer som f.eks. feber, sår, usædvanlig træthed eller tandproblemer, da disse kan være tegn på infektion.
English: RA-BEAM MTX-IR patients
Danish: RA-BEAM MTX-IR patienter
English: Polyvinylchloride/polyethylene/polychlorotrifluoroethylene - aluminium blisters in cartons of 14, 28, 35, 56, 84 or 98 film-coated tablets.
Danish: Polyvinylchlorid/polyethylen/polychlortrifluorethylen - aluminium-blistere i kartoner med 14, 28, 35, 56, 84 eller 98 filmovertrukne tabletter.
English: Therefore, the PRAC requests the MAH to update section 4.4 of the SmPC to modify the wording on “Venous Thromboembolism” to indicate that if clinical features of DVT/PE occur, baricitinib treatment should be discontinued and to update section 4.8 of the SmPC to add the adverse reaction pulmonary embolism and deep vein thrombosis with a frequency not known.
Danish: Derfor anmoder PRAC om, at MAH opdaterer afsnit 4.4 i SmPCet ved at ændre ordlyden for ”venøs tromboemboli” for at indikere, at hvis der opstår kliniske tilfælde af DVT/PE, skal behandling med baricitinib seponeres, samt at MAH opdaterer afsnit 4.8 i SmPCet ved at tilføje bivirkningerne lungeemboli og dyb venetrombose med hyppigheden ikke kendt.
English: Week 24 0.14 0.06 0.03 0.29 0.12** Week 52 0.21 0.25 0.06 0.58 0.21*** 0.19** Proportion of patients with no radiographic progressionb:
Danish: Uge 24 0,14 0,06 0,03 0,29 0,12** Uge 52 0,21 0,25 0,06 0,58 0,21*** 0,19** Andel af patienter uden radiologisk progressionb:
English: • Primary endpoint: ACR20 at week 24
Danish: • Primært endepunkt: ACR20 ved uge 24
English: Data concerning use of baricitinib with potent immunosuppressive medicinal products (e.g., azathioprine, tacrolimus, ciclosporin) are limited and caution should be exercised when using such combinations (see section 4.5).
Danish: Mængden af data vedrørende anvendelse af baricitinib sammen med potente immunsupprimerende lægemidler (f.eks. azathioprin, tacrolimus, ciclosporin) er begrænset, og der skal udvises forsigtighed ved anvendelse af sådanne kombinationer (se pkt.
English: Significant increases (> 5 x ULN) occurred in 0.8 % of patients treated with Olumiant and 0.3 % of patients treated with placebo.
Danish: Der forekom signifikante stigninger (> 5 x ULN) hos 0,8 % af de patienter, der blev behandlet med Olumiant, og hos 0,3 % af de patienter, der fik placebo.
English: Body weight, sex, race, and ethnicity did not have a clinically relevant effect on the PK of baricitinib.
Danish: Legemsvægt, køn, race og etnicitet havde ingen klinisk relevant indvirkning på baricitinibs farmakokinetik.
English: In rat and rabbit reproductive toxicology studies, baricitinib was shown to reduce foetal growth/weight and produce skeletal malformations (at exposures of approximately 10 and 39 times the human exposure, respectively).
Danish: I studier af reproduktionstoksicitet hos rotter og kaniner reducerede baricitinib føtal vækst/vægt og medførte skeletale misdannelser (ved eksponeringer på henholdsvis ca. 10 og 39 gange eksponeringen hos mennesker).
English: The influence of baricitinib on the humoral response to non-live vaccines was evaluated in 106 RA patients under stable treatment with baricitinib 2 or 4 mg, receiving inactivated pneumococcal or tetanus vaccination.
Danish: Baricitinibs påvirkning af det humorale respons på inaktiverede vacciner blev evalueret hos 106 reumatoid artritis patienter i stabil behandling med baricitinib 2 eller 4 mg.
English: The most common concomitant DMARDs in these subjects were MTX (79% of patients), hydroxychloroquine (19%), leflunomide
Danish: De hyppigste samtidige DMARDs hos disse personer var MTX (79 % af patienterne), hydroxychloroquin (19 %), leflunomid (11 %) og sulfasalazin (9 %).
English: • talc
Danish: • talcum
English: Administration of baricitinib resulted in a dose dependent inhibition of IL-6 induced STAT3 phosphorylation in whole blood from healthy subjects with maximal inhibition observed 2 hours after dosing which returned to near baseline by 24 hours.
Danish: Administration af baricitinib resulterede i en dosisafhængig hæmning af IL-6-induceret fosforylering af STAT3 i helblod fra raske forsøgspersoner med maksimal hæmning 2 timer efter dosering og tilbagevenden til nær baseline-niveau i løbet af 24 timer.
English: Use of baricitinib with potent immunosuppressive medicinal products such as azathioprine, tacrolimus, or ciclosporin was limited in clinical studies of baricitinib, and a risk of additive immunosuppression cannot be excluded (see section 4.4).
Danish: Anvendelse af baricitinib sammen med potente immunsupprimerende lægemidler som f.eks. azathioprin, tacrolimus eller ciclosporin var begrænset i kliniske studier med baricitinib, og en risiko for additiv immunsuppression kan ikke udelukkes (se pkt.
English: Olumiant contains the active substance baricitinib.
Danish: Olumiant indeholder det aktive stof baricitinib.
English: Mean apparent clearance (CL/F) and half-life in patients with rheumatoid arthritis was 9.42 L/hr (CV = 34.3 %) and 12.5 hrs (CV = 27.4 %), respectively.
Danish: Den gennemsnitlige tilsyneladende clearance (CL/F) og halveringstid hos patienter med reumatoid artritis er henholdsvis 9,42 l/time (CV = 34,3 %) og 12,5 time (CV = 27,4 %).
English: Tell your doctor if you get a painful swollen leg, chest pain, or shortness of breath as these can be signs of blood clots in the veins - If you notice any of the following serious side effects you need to tell a doctor straight away: - chest tightness - wheezing - severe dizziness or light-headedness - swelling of the lips, tongue or throat - hives (itching or skin rash)
Danish: Fortæl lægen, hvis du får et smertefuldt hævet ben, brystsmerter eller åndenød, da disse kan være tegn på blodpropper i venerne - Fortæl det straks til lægen, hvis du får nogen af følgende alvorlige bivirkninger: trykken for brystet hiven efter vejret svær ørhed eller svimmelhed hævelse af læber, tunge eller hals nældefeber (kløe eller hududslæt)
English: • Contact details of the prescriber
Danish: • Kontaktoplysninger på den ordinerende læge.
English: No dose adjustment is required in patients with mild or moderate hepatic impairment.
Danish: Det er ikke nødvendigt at justere dosis hos patienter med let eller moderat nedsat leverfunktion.
English: Very common side effects (may affect more than 1 in 10 people): - throat and nose infections - high levels of blood fat (cholesterol) shown by blood test
Danish: Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 behandlede): - infektioner i hals og næse - højt niveau af fedt (kolesterol) i blodet, påvises i en blodprøve
English: • Primary endpoint: ACR20 at week 12
Danish: • Primært endepunkt: ACR20 ved uge 12
English: Patients should be managed according to international clinical guidelines for hyperlipidaemia
Danish: Patienterne bør håndteres i overensstemmelse med internationale kliniske retningslinjer vedrørende hyperlipidæmi.
English: Do not take Olumiant: - if you are allergic to baricitinib or any of the other ingredients of this medicine (listed in section 6).
Danish: Det skal du vide, før du begynder at tage Olumiant Tag ikke Olumiant: - hvis du er allergisk over for baricitinib eller et af de øvrige indholdsstoffer i Olumiant (angivet i afsnit 6).
English: The use of baricitinib has not been studied in patients with severe hepatic impairment.
Danish: Baricitinib er ikke blevet undersøgt hos patienter med svært nedsat leverfunktion.
English: There was no clinically relevant effect on the PK of baricitinib in patients with mild or moderate hepatic impairment.
Danish: Der var ingen klinisk relevant indvirkning på baricitinibs farmakokinetik hos patienter med let eller moderat nedsat leverfunktion.
English: Increases in alanine transaminase (ALT) and aspartate transaminase (AST) to ≥ 5 and ≥ 10 x upper limit of normal (ULN) were reported in less than 1 % of patients in clinical trials.
Danish: Stigninger i alanin-aminotransferase (ALAT) og aspartat-aminotransferase (ASAT) til ≥ 5 og ≥ 10 x den øvre normalgrænse (ULN) blev rapporteret hos under 1 % af patienterne i kliniske studier.
English: Other intrinsic Factors
Danish: Andre faktorer
English: RA-BEGIN MTX-naïve patients
Danish: RA-BEGIN MTX-naïve patienter
English: Differences in efficacy between the 4 mg and the 2 mg doses were most notable in the bDMARD-IR population (RA-BEACON), in which statistically significant improvements in the ACR components of swollen joint count, tender joint count and ESR were shown for Olumiant 4 mg compared to placebo at Week 24 but not for Olumiant 2 mg compared to placebo.
Danish: Forskellen i effekt mellem doserne på 4 mg og 2 mg var mest udtalt hos bDMARD-IR-populationen (RA-BEACON), hvor der i uge 24 blev påvist statistisk signifikante forbedringer i ACRkomponenterne antal hævede led, antal ømme led og ESR for Olumiant 4 mg sammenlignet med placebo, men ikke for Olumiant 2 mg sammenlignet med placebo.
English: Patients should be screened for tuberculosis (TB) before starting Olumiant therapy.
Danish: Patienter bør screenes for tuberkulose (TB), før behandling med Olumiant indledes.
English: The proportion of patients with no radiographic progression (mTSS change ≤ 0) was significantly higher with Olumiant 4 mg compared to placebo at weeks 24 and 52.
Danish: Andelen af patienter uden radiologisk progression (mTSS-ændring ≤ 0) var signifikant højere med Olumiant 4 mg sammenlignet med placebo ved uge 24 og 52.
English: In all 4 studies, a significantly higher proportion of patients treated with Olumiant 4 mg compared to placebo or MTX achieved low disease activity or remission (DAS28-ESR or DAS28-hsCRP ≤ 3.2 and DAS28-ESR or DAS28-hsCRP < 2.6) at Weeks 12 and 24.
Danish: I alle 4 studier havde en signifikant større andel patienter behandlet med Olumiant 4 mg sammenlignet med placebo og MTX opnået lav sygdomsaktivitet eller remission (DAS28-ESR eller DAS28-hsCRP ≤ 3,2 og DAS28-ESR eller DAS28-hsCRP < 2,6) ved uge 12 og 24.
English: Potential for other medicinal products to affect the pharmacokinetics of baricitinib
Danish: Andre lægemidlers potentiale til at påvirke farmakokinetikken af baricitinib
English: Modified Total Sharp Score, mean change from baseline:
Danish: Modified Total Sharp Score - gennemsnitlig ændring i forhold til baseline:
English: In RA-BEAM, treatment with Olumiant resulted in significant improvement in patient and physician global assessments, HAQ-DI, pain assessment and CRP at Weeks 12, 24 and 52 compared to adalimumab.
Danish: I RA-BEAM resulterede behandling med Olumiant i en signifikant forbedring i patientens og lægens samlede vurderinger, HAQ-DI, smertevurdering og CRP ved uge 12, 24 og 52 sammenlignet med adalimumab.
English: You may need blood tests before you start Olumiant, or while you are taking it, to check if you have a low red blood cell count (anaemia), low white blood cell count (neutropaenia or lymphopaenia), high blood fat (cholesterol) or high levels of liver enzymes, to ensure that treatment with Olumiant is not causing problems.
Danish: Det kan være, at du skal have taget blodprøver, før du starter med Olumiant, eller mens du tager det, for at kontrollere, om du har et lavt antal røde blodlegemer (anæmi), et lavt antal hvide blodlegemer (neutropeni eller lymfopeni), et højt indhold af fedt (kolesterol) i blodet eller høje niveauer af leverenzymer.
English: - If you forget your dose for an entire day, just skip the missed dose and take only a single dose as usual the following day.
Danish: Hvis du har glemt at tage Olumiant - Hvis du har glemt en dosis, så tag den, så snart du kommer i tanke om det. - Hvis du har glemt din dosis en hel dag, skal du springe den glemte dosis over og kun tage en enkelt dosis som sædvanlig den efterfølgende dag.
English: No association was observed between increased platelet counts and adverse events of a thrombotic nature.
Danish: Der blev ikke observeret nogen sammenhæng mellem forhøjet trombocyttal og bivirkninger af trombotisk karakter.
English: Degeneration of the sternal growth plate was observed in some dogs, at low incidence and also in control animals, but with a dose-effect relationship regarding severity.
Danish: Hos hunde - også hos kontroldyrblev der observeret degeneration af brystbenets epifyseskive med en lav incidens, men med en sammenhæng mellem dosis og effekt med hensyn til sværhedsgrad.
English: RA-BEAM (52 weeks)
Danish: RA-BEAM (52 uger)
English: Baricitinib is associated with an increased rate of infections such as upper respiratory tract infections compared to placebo (see section 4.8).
Danish: Baricitinib er forbundet med en øget forekomst af infektioner, f.eks. infektioner i øvre luftveje, sammenlignet med placebo (se pkt.
English: Olumiant can reduce your body's ability to fight infections and may make an existing infection worse or increase the chance of you getting a new infection - have, or have previously had, tuberculosis.
Danish: Olumiant kan nedsætte kroppens evne til at bekæmpe infektioner og kan forværre en eksisterende infektion eller øge risikoen for, at du får en ny infektion.
English: Mean serum IgG, IgM, and IgA values decreased by 12 weeks after starting treatment with Olumiant, and remained stable at a lower value than baseline through at least 104 weeks.
Danish: De gennemsnitlige serumværdier af IgG, IgM og IgA faldt frem til 12 uger efter opstart af Olumiant og forblev stabile ved en værdi lavere end baseline-værdi frem til mindst uge 104.
English: A statistically significantly greater proportion of patients treated with Olumiant 4 mg compared to placebo or MTX achieved remission, as defined by SDAI ≤ 3.3 and CDAI ≤ 2.8, at weeks 12 and 24 (Table 4).
Danish: En statistisk signifikant større andel patienter behandlet med Olumiant 4 mg sammenlignet med placebo eller MTX havde opnået remission, defineret som SDAI ≤ 3,3 og CDAI ≤ 2,8, ved uge 12 og 24 (tabel 4).
English: It belongs to a group of medicines called Janus kinase inhibitors, which help to reduce inflammation.
Danish: Det tilhører en gruppe af lægemidler, der kaldes Janus-kinase-hæmmere, som hjælper med at reducere inflammation (en betændelseslignende reaktion).
English: 5 Most common concomitant cDMARDs included MTX, hydroxychloroquine, leflunomide and sulfasalazine
Danish: 5De hyppigste samtidigt administrerede cDMARDs omfattede MTX, hydroxychloroquin, leflunomid og sulfasalazin.
English: In treatment naïve patients, combination with methotrexate resulted in increased frequency of infections compared to baricitinib monotherapy.
Danish: Hos tidligere ubehandlede patienter resulterede kombination med methotrexat i en øget hyppighed af infektioner sammenlignet med monoterapi med baricitinib.
English: Polyvinylchloride/aluminium/oriented polyamide - aluminium perforated unit dose blisters in cartons of 28 x 1 or 84 x 1 film-coated tablets.
Danish: Perforerede enkeltdosis-polyvinylchlorid/aluminium/orienteret polyamid - aluminium-blistere i kartoner med 28 x 1 eller 84 x 1 filmovertrukne tabletter.
English: If clinical features of DVT/PE occur, Olumiant treatment should be discontinued and patients should be evaluated promptly, followed by appropriate treatment.
Danish: Behandling med Olumiant skal seponeres, hvis der opstår kliniske symptomer på DVT/PE, og patienten skal straks vurderes efterfulgt af en passende behandling.
English: For most patients, changes in immunoglobulins occurred within the normal reference range.
Danish: Hos de fleste patienter lå immunglobulin-værdierne fortsat inden for det normale referenceinterval.
English: Hypercholesterolaemiac
Danish: Hyperkolesterolæmic
English: Patients should not be immunised using live attenuated vaccines shortly before or during treatment with Olumiant.
Danish: Patienten må ikke vaccineres med svækkede, ikke-levende vacciner under eller umiddelbart før behandling med Olumiant.
English: Uncommon side effects (may affect up to 1 in 100 people): - low number of white bloods cells (neutrophils), shown by blood test - increase in an enzyme called creatine kinase, shown by blood test - high levels of blood fat (triglycerides), shown by blood test - acne - weight gain - swelling of the face - urticaria - blood clots in the blood vessels of the lungs - blood clot in the veins of the legs or pelvis, called a deep vein thrombosis (DVT)
Danish: Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 behandlede): - lavt antal hvide blodlegemer (neutrofiler), påvises i en blodprøve - stigning i niveauet af et enzym, der kaldes kreatinkinase, påvises i en blodprøve - højt niveau af fedt (triglycerider) i blodet, påvises i en blodprøve - akne - vægtstigning - hævelse i ansigtet - nældefeber - blodpropper i blodårerne i lungerne - blodprop i venerne i benene eller bækkenet, kaldet en dyb venetrombose (DVT)
English: If you have reduced kidney function, the recommended dose of Olumiant is 2 mg once a day.
Danish: Hvis du har nedsat nyrefunktion, er den anbefalede dosis af Olumiant 2 mg én gang om dagen.
English: Week 24 0.47 0.33 0.26*
Danish: Uge 24 0,47 0,33 0,26*
English: In vitro, baricitinib is a cytochrome P450 enzyme (CYP)3A4 substrate although less than 10 % of the dose is metabolised via oxidation.
Danish: In vitro er baricitinib et CYP3A4-substrat, selvom under 10 % af dosis metaboliseres via oxidation.
English: Mean absolute lymphocyte count increased by 1 week after starting treatment with Olumiant, returned to baseline by week 24, and then remained stable through at least 104 weeks.
Danish: Det gennemsnitlige absolutte lymfocyttal steg frem til 1 uge efter opstart af Olumiant, var vendt tilbage til baseline-niveau ved uge 24 og forblev stabilt frem til mindst uge 104.
English: Patients should be instructed to seek immediate medical attention, if signs or symptoms suggesting infection appear.
Danish: Opfordring til patienten om omgående at søge læge, hvis der forekommer symptomer, som tyder på infektion.
English: How to take Olumiant
Danish: Sådan skal du tage Olumiant
English: Viral reactivation, including cases of herpes virus reactivation (e.g., herpes zoster, herpes simplex), were reported in clinical studies (see section 4.8).
Danish: I kliniske studier blev der rapporteret viral reaktivering, herunder tilfælde af reaktivering af herpesvirus (f.eks. herpes zoster, herpes simplex) (se pkt.
English: In controlled studies, for up to 16 weeks, the incidence rate of all infections (rate of patients with ≥ 1 event per 100 patient-years of exposure) was 101 with Olumiant compared to 83 in the placebo group.
Danish: I kontrollerede studier var incidensraten af alle infektioner (forekomst af patienter med ≥ 1 hændelse pr. 100 patientårs eksponering) over de første 16 uger, 101 med Olumiant sammenlignet med 83 i placebogruppen.
English: The recommended dose of Olumiant is 4 mg once daily.
Danish: Den anbefalede dosis af Olumiant er 4 mg én gang daglig.